205 related articles for article (PubMed ID: 28452169)
1. Melanoma patient response to nivolumab treatment for metastatic lung lesions: Multi-OMICS analysis in Project HOPE.
Kiyohara Y; Yoshikawa S; Otsuka M; Kondou R; Iizuka A; Nonomura C; Ohshima K; Urakami K; Kusuhara M; Nagashima T; Sugino T; Yamaguchi K; Akiyama Y
J Dermatol; 2017 Oct; 44(10):1156-1159. PubMed ID: 28452169
[TBL] [Abstract][Full Text] [Related]
2. Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE.
Yoshikawa S; Kiyohara Y; Otsuka M; Kondou R; Nonomura C; Miyata H; Iizuka A; Ohshima K; Urakami K; Nagashima T; Kusuhara M; Sugino T; Mochizuki T; Yamaguchi K; Akiyama Y
Anticancer Res; 2017 Mar; 37(3):1321-1328. PubMed ID: 28314298
[TBL] [Abstract][Full Text] [Related]
3. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
[TBL] [Abstract][Full Text] [Related]
4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
5. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
6. Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells.
Kanameishi S; Otsuka A; Nonomura Y; Fujisawa A; Endo Y; Kabashima K
Ann Oncol; 2016 Mar; 27(3):546-7. PubMed ID: 26602778
[No Abstract] [Full Text] [Related]
7. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
8. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
9. Immune response-associated gene profiling in Japanese melanoma patients using multi-omics analysis.
Akiyama Y; Kiyohara Y; Yoshikawa S; Otsuka M; Kondou R; Nonomura C; Miyata H; Iizuka A; Ashizawa T; Ohshima K; Urakami K; Nagashima T; Kusuhara M; Sugino T; Yamaguchi K
Oncol Rep; 2018 Mar; 39(3):1125-1131. PubMed ID: 29286146
[TBL] [Abstract][Full Text] [Related]
10. Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy.
Nomura H; Takahashi H; Suzuki S; Kurihara Y; Chubachi S; Kawada I; Yasuda H; Betsuyaku T; Amagai M; Funakoshi T
J Dermatol; 2017 Jul; 44(7):818-821. PubMed ID: 28295542
[TBL] [Abstract][Full Text] [Related]
11. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
Shibaki R; Murakami S; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Kusumoto M; Yamamoto N; Ohe Y
Med Oncol; 2019 Apr; 36(6):49. PubMed ID: 31030326
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
[TBL] [Abstract][Full Text] [Related]
13. Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient.
Kanno H; Ishida K; Yamada W; Nishida T; Takahashi N; Mochizuki K; Mizuno Y; Matsuyama K; Takahashi T; Seishima M
J Infect Chemother; 2017 Nov; 23(11):774-777. PubMed ID: 28527652
[TBL] [Abstract][Full Text] [Related]
14. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
Park JH; You GL; Ahn MJ; Kim SW; Hong MH; Han JY; Ock CY; Lee JS; Oh IJ; Lee SY; Kim CH; Min YJ; Choi YH; Ryu JS; Park SH; Ahn HK; Shim BY; Lee KH; Lee SY; Kim JS; Yi J; Choi SK; An H; Kang JH
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2459-2469. PubMed ID: 33523301
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockade.
Naidoo J; Page DB; Wolchok JD
Hematol Oncol Clin North Am; 2014 Jun; 28(3):585-600. PubMed ID: 24880949
[TBL] [Abstract][Full Text] [Related]
16. Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
Haratake N; Toyokawa G; Tagawa T; Kozuma Y; Matsubara T; Takamori S; Akamine T; Yamada Y; Oda Y; Maehara Y
Anticancer Res; 2017 Oct; 37(10):5713-5717. PubMed ID: 28982891
[TBL] [Abstract][Full Text] [Related]
17. Complete response to anti-PD-1 nivolumab in massive skin metastasis from melanoma: efficacy and tolerability in an elderly patient.
Sponghini A; Patrucco F; Giorgione R; Farinelli P; Zottarelli F; Rondonotti D; Savoia P
Anticancer Drugs; 2017 Aug; 28(7):808-810. PubMed ID: 28489616
[TBL] [Abstract][Full Text] [Related]
18. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab success in untreated metastatic melanoma.
Wilkinson E
Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638562
[No Abstract] [Full Text] [Related]
20. Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Bottlaender L; Breton AL; de Laforcade L; Dijoud F; Thomas L; Dalle S
J Immunother Cancer; 2017 Jul; 5(1):57. PubMed ID: 28716106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]